SetPoint Medical Expands RA Neuroimmune Therapy in Oregon

Valencia, California, USA, September 16, 2026

OHSU Introduces SetPoint System in Pacific Northwest

The first clinical use of the SetPoint System at OHSU brings a device-based neuroimmune modulation approach to patients with rheumatoid arthritis in Oregon and surrounding areas. OHSU clinicians described the technology as an example of how advances in neuromodulation can extend beyond traditional neurological conditions into immune-mediated diseases. The collaboration between SetPoint Medical and the academic medical center is intended to expand patient access to an FDA-approved treatment option for people whose rheumatoid arthritis remains inadequately controlled or who cannot tolerate certain advanced drug therapies. SetPoint Medical said Oregon now joins a growing number of U.S. markets where patients can access its therapy as the company continues establishing relationships with medical centers and rheumatology practices nationwide.

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks tissues associated with the joints, potentially causing pain, swelling, stiffness and progressive joint damage. Although pharmaceutical therapies have substantially expanded treatment options for RA, some patients continue to experience inadequate disease control or treatment intolerance. SetPoint Medical estimates that approximately 1.5 million adults in the United States live with rheumatoid arthritis, highlighting the continuing need for additional therapeutic approaches.

Vagus Nerve Stimulation Targets Immune Regulation

The scientific foundation of the SetPoint System is vagus nerve-mediated neuroimmune modulation. The implanted device delivers targeted electrical stimulation to the left vagus nerve, with the objective of activating the body’s innate anti-inflammatory pathways and influencing immune activity associated with rheumatoid arthritis. This represents a different therapeutic approach from conventional drug-based treatment, using controlled electrical stimulation rather than administering a systemic pharmaceutical agent.

The SetPoint System includes an implantable neurostimulator, while patients use a wireless charger worn around the neck for several minutes each week to recharge the device. The system is specifically indicated for adults with moderately to severely active RA who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic DMARDs. The company states that the device should not be used in people who have undergone a vagotomy or splenectomy, or when a healthcare provider determines that its use is unsafe.

Neuroimmune Modulation Expands Beyond Neurology

The clinical introduction of the SetPoint System illustrates the growing intersection between medical device technology, neuroscience and immunology. SetPoint Medical is developing its integrated neurostimulation platform with a broader focus on chronic autoimmune diseases, while its current FDA-approved indication is rheumatoid arthritis. The company has also stated that it plans to evaluate the platform in other conditions, including multiple sclerosis and Crohn’s disease, although those applications remain outside the current approved indication.

The OHSU milestone follows the introduction of SetPoint Therapy at additional U.S. centers, including treatment expansion into Minnesota and North Carolina. As clinical adoption develops, continued real-world experience and clinical evidence will provide further information about the role of neuroimmune modulation in rheumatoid arthritis care. The Pacific Northwest launch therefore represents both a regional access milestone and another development in the emerging field of bioelectronic medicine, where targeted neural stimulation is being investigated as a means of influencing biological processes involved in chronic disease.

Source: SetPoint Medical press release